Pfizer Completes Acquisition Of Wyeth
October 15 2009 - 11:49AM
Business Wire
Pfizer (NYSE: PFE) and Wyeth (NYSE: WYE) announced today that
Pfizer has completed its acquisition of Wyeth following the receipt
of regulatory approval from all government authorities required by
the merger agreement and approval by Wyeth shareholders. Under the
terms of the transaction, each outstanding share of Wyeth common
stock has been converted into the right to receive $33 in cash
(without interest) and 0.985 of a share of Pfizer common stock.
Effective as of the close of trading today, October 15, 2009,
Wyeth common stock (NYSE: WYE) will cease trading.
Pfizer and Wyeth will begin joint operations tomorrow, October
16, 2009. The merger of local Pfizer and Wyeth entities may be
pending in various jurisdictions and integration is subject to
completion of various local legal and regulatory obligations.
Pfizer has appointed Computershare Trust Company as exchange
agent and paying agent in connection with the merger. Wyeth
registered shareholders with questions regarding payment for Wyeth
common stock should contact Computershare Trust Company at (877)
745-9320 and outside the U.S., Canada and Puerto Rico at +1
(781)575-4336. Additional information will also be mailed to Wyeth
registered shareholders. Wyeth shareholders who hold stock through
a broker or bank should receive information regarding the
conversion of their shares from the party holding their shares.
Pfizer Inc: Working together for a healthier world™
At Pfizer, we apply science and our global resources to improve
health and well-being at every stage of life. We strive to set the
standard for quality, safety and value in the discovery,
development and manufacturing of medicines for people and animals.
Our diversified global health care portfolio includes human and
animal biologic and small molecule medicines and vaccines, as well
as nutritional products and many of the world’s best-known consumer
products. Every day, Pfizer colleagues work across developed and
emerging markets to advance wellness, prevention, treatments and
cures that challenge the most feared diseases of our time.
Consistent with our responsibility as the world’s leading
biopharmaceutical company, we also collaborate with health care
providers, governments and local communities to support and expand
access to reliable, affordable health care around the world.
For more than 150 years, Pfizer has worked to make a
difference for all who rely on us. To learn more about our
commitments, please visit us at www.pfizer.com
Wyeth is now a wholly owned subsidiary of Pfizer Inc. The merger
of local Wyeth and Pfizer entities may be pending in various
jurisdictions and integration is subject to completion of various
local legal and regulatory obligations.
More information is available at www.pfizer.com.
Follow Pfizer on www.Twitter.com/pfizer_news.
Wyeth (NYSE:WYE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Wyeth (NYSE:WYE)
Historical Stock Chart
From Sep 2023 to Sep 2024